ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary

Adc Therapeutics

13/08/2026 14:32

ADC Therapeutics SA ADCT.N reported a quarterly adjusted loss of 9 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -38 cents.  The mean expectation of five analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -24 cents to -19 cents per share.
Revenue rose 2.2% to $19.25 million from a year ago; analysts expected $19.38 million. 
ADC Therapeutics SA's reported EPS for the quarter was a loss of 11 cents​.
The company reported a quarterly loss of $16.57 million.
ADC Therapeutics SA shares had risen by 15.0% this quarter and lost 65.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 1.8% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for ADC Therapeutics SA is $2.50, about 50.8% above its last closing price of $1.23
This summary was machine generated from LSEG data August 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.21
-0.09
Beat
Mar. 31 2026 
-0.21
-0.13
Beat
Dec. 31 2025 
-0.27
-0.04
Beat
Sep. 30 2025 
-0.36
-0.30
Beat